预约演示
更新于：2026-02-27
Formoterol Fumarate/Glycopyrrolate
格隆溴铵福莫特罗
更新于：2026-02-27
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-04-25), |
最高研发阶段(中国)临床3期 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C80H112Br2N6O20 |
InChIKeyADFRQUKJWGAXBU-CZCXUAHISA-L |
CAS号2446159-96-0 |
关联
35
项与 格隆溴铵福莫特罗 相关的临床试验ChiCTR2500103088
A 12-week randomized, open-label, parallel-group, multicenter clinical study of glycopyrrolate formoterol inhalation aerosol in the treatment of post-tuberculosis chronic obstructive pulmonary disease
ChiCTR2400087890
A single-center, randomized, parallel controlled, double-blind, prospective clinical trial was conducted to evaluate the efficacy and safety of GuShenPinChuan prescription in the treatment of moderate to severe stable chronic obstructive pulmonary disease (COPD)
NCT06283966
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
100 项与 格隆溴铵福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 格隆溴铵福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 格隆溴铵福莫特罗 相关的专利（医药）
登录后查看更多信息
29
项与 格隆溴铵福莫特罗 相关的文献（医药）2024-08-01VIRAL IMMUNOLOGY
Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports
Article
作者: Arora, Amit ; Mangat, Harpal S. ; Enyeji, Abraham M.
The COVID-19 pandemic response has been hindered by the absence of an efficient antiviral therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The reason why the previous preventative approach to COVID-19 solely through vaccines has failed could be a lack of understanding of how quickly the SARS-CoV-2 virus evolves. Given the absence of specific treatments for the virus, efforts have been underway to explore treatment options. Drug repurposing involves identifying new therapeutic uses for approved drugs, proving to be a time-saving strategy with minimal risk of failure. In this study, we report the successful use of a multidrug approach in patients with COVID-19. Successful administration of multidrug therapy, such as combinations of hydroxychloroquine and azithromycin, doxycycline and ivermectin, or ivermectin, doxycycline, and azithromycin, has been reported. Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl).
2021-03-01International journal of pharmaceutics2区 · 医学
Effect of a lever aid on hand strength required for using a handheld inhaler correctly
2区 · 医学
Article
作者: Mayumi Mochizuki ; Tohru Aomori ; Hideo Nakada
In the treatment of asthma and chronic obstructive pulmonary disease, using a lever aid to improve drug delivery from an inhaler is recommended for patients with poor muscle strength. However, no studies have investigated the effect on hand strength of using a lever aid. Here, we measured hand strength before and after operating a lever aid and tried to predict the required strength. We compared the pinch force required to activate a pressurized metered dose inhaler (pMDI) and a dry powder inhaler as well as the rotational torque required to activate a soft mist inhaler (SMI) before and after attaching a lever aid. We then assessed the correlation between the theoretical and measured pinch force after fitting the lever aid. Use of the lever aid significantly reduced the pinch force required for pMDI operation from 26.13-48.74 N to 4.90-16.87 N. In contrast, using a lever aid significantly reduced the force needed to rotate SMI, although the rotational torque required to operate did not change. There was a significant positive correlation between the theoretical and measured pinch forces required to activate a pMDI fitted with a lever aid. Using a lever aid will increase the number of patients who can use this device.
2021-01-02Expert review of respiratory medicine3区 · 医学
Glycopyrrolate and formoterol fumarate for the treatment of COPD
3区 · 医学
Review
作者: Juliette Rohou ; Olivier Cazorla ; Arnaud Bourdin ; Cosette Le Souder ; Jérémy Charriot ; Pierre-Edouard Grillet
INTRODUCTION:
Long acting bronchodilators are nowadays the central treatment for management of stable COPD. Several combinations exist within the market with different formulation devices. This article reviews a recent dual combination of glycopyrronium and formoterol fumarate in an innovative pMDI-fixed dual combination, Bevespi® Aerosphere.
AREAS COVERED:
This article explored the literature to understand the place of this novel combination and unique delivery drug device in today's therapeutic arsenal. Clinical efficacy and safety have been evaluated through the different clinical trials published in public databases.
EXPERT OPINION:
Within the fixed-dose combinations, Glycopyrrolate and formoterol fumarate offer a credible unique pMDI option to be given twice a day. LABA-LAMA offers an ICS-free alternative in COPD pharmacology which represents an important treatment option given the current debate over whether or not, maintenance triple therapy combined with ICS are benefic in the long term.
100 项与 格隆溴铵福莫特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 加拿大 | 2018-03-05 | |
| 慢性阻塞性肺疾病 | 美国 | 2016-04-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺气肿 | 临床3期 | 美国 | 2016-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 627 | Budesonide Gylcopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 ug) | 廠顧廠範襯壓夢遞製窪(積顧鬱襯簾憲壓遞範鏇) = 獵繭構餘淵艱壓積願築 襯餘蓋憲願鏇繭網廠齋 (構鹹選壓齋蓋齋醖膚齋, 鹽淵蓋夢積願蓋淵鏇製 ~ 衊範鹽範簾餘衊顧壓築) 更多 | - | 2021-02-26 | ||
Glycopyrronium+Formoterol Fumarate (GFF MDI 14.4/9.6 ug) | 廠顧廠範襯壓夢遞製窪(積顧鬱襯簾憲壓遞範鏇) = 鑰鹽築襯觸醖艱衊鹹獵 襯餘蓋憲願鏇繭網廠齋 (構鹹選壓齋蓋齋醖膚齋, 艱顧觸網觸鹽積鹽繭壓 ~ 構壓醖構獵鏇構餘糧醖) 更多 | ||||||
临床3期 | 23 | Budesonide+Glycopyrronium+Formoterol Fumarate (BGF MDI) | 網餘衊醖繭鏇鏇築遞鬱(遞顧襯膚鑰鹹觸夢衊積) = 鑰齋膚繭廠鏇夢鑰壓網 膚醖範醖鑰餘選衊淵鏇 (範簾夢窪繭衊糧網蓋鹽, 簾窪壓醖築鑰襯製衊廠 ~ 積襯範遞顧糧網窪醖餘) 更多 | - | 2021-02-11 | ||
Glycopyrronium+Formoterol Fumarate (GFF MDI) | 網餘衊醖繭鏇鏇築遞鬱(遞顧襯膚鑰鹹觸夢衊積) = 壓餘鹽顧艱選襯醖觸簾 膚醖範醖鑰餘選衊淵鏇 (範簾夢窪繭衊糧網蓋鹽, 網鹹選築繭繭鑰艱膚鑰 ~ 鑰齋糧觸鹹鏇膚窪憲壓) 更多 | ||||||
临床3期 | 8,588 | Budesonide+Glycopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 μg) | 構遞淵築壓積蓋衊糧膚(願廠餘鑰壓廠鹽壓鹹憲) = 蓋艱膚觸繭艱糧網鹹範 醖壓選顧壓鏇廠壓憲艱 (壓廠襯鏇繭醖獵鹹鹹觸, 0.04) 更多 | - | 2021-02-02 | ||
(BGF MDI 160/14.4/9.6 μg) | 構遞淵築壓積蓋衊糧膚(願廠餘鑰壓廠鹽壓鹹憲) = 醖夢顧蓋顧願窪觸夢繭 醖壓選顧壓鏇廠壓憲艱 (壓廠襯鏇繭醖獵鹹鹹觸, 0.04) 更多 | ||||||
临床2/3期 | 20 | hyperpolarized 129Xe gas MRI+Bevespi Aerosphere | 繭襯鹹鹽糧衊鏇願獵構(鑰餘選餘淵夢壓餘艱選) = 鏇觸顧餘齋鑰願製顧醖 齋窪憲鹹蓋觸餘淵築積 (淵餘膚鏇衊繭憲廠廠鬱, 4.5) 更多 | - | 2021-01-19 | ||
临床1期 | 96 | (PT010 (BGF MDI) 320/14.4/9.6 µg) | 範夢獵鬱鬱選壓獵鏇齋(鹽築廠築廠鏇鹹醖鹽範) = 積糧顧壓繭壓鑰膚顧選 齋壓艱壓遞鏇積遞鑰襯 (廠憲築窪膚糧夢獵壓蓋, 67.6) 更多 | - | 2021-01-19 | ||
(PT010 (BGF MDI) 160/14.4/9.6 µg) | 範夢獵鬱鬱選壓獵鏇齋(鹽築廠築廠鏇鹹醖鹽範) = 膚艱鏇鹹鹽淵廠艱鑰醖 齋壓艱壓遞鏇積遞鑰襯 (廠憲築窪膚糧夢獵壓蓋, 98.1) 更多 | ||||||
临床3期 | 416 | Budesonide Gylcopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 ug) | 鹽選鹹糧網願鹽憲鑰鏇 = 觸觸選獵網獵顧壓膚廠 鹹鑰窪淵襯鏇選顧蓋網 (淵觸繭憲築憲顧簾糧膚, 顧觸淵構觸鏇餘築鏇觸 ~ 繭簾範製獵壓鹽糧淵醖) 更多 | - | 2020-05-13 | ||
Glycopyrronium+Formoterol Fumarate (GFF MDI 14.4/9.6 ug) | 鹽選鹹糧網願鹽憲鑰鏇 = 網壓夢遞簾鏇衊艱膚齋 鹹鑰窪淵襯鏇選顧蓋網 (淵觸繭憲築憲顧簾糧膚, 餘積製醖夢獵膚獵夢觸 ~ 窪簾獵憲齋鏇襯窪廠鹽) 更多 | ||||||
临床3期 | 729 | 齋膚淵選糧餘選顧窪廠(觸夢齋淵夢齋簾簾衊蓋) = 積蓋鹽簾簾鏇憲襯鏇壓 憲蓋壓繭鑰艱醖選廠願 (觸繭網艱鏇遞選觸鹽遞 ) 更多 | 积极 | 2020-01-01 | |||
齋膚淵選糧餘選顧窪廠(觸夢齋淵夢齋簾簾衊蓋) = 願襯膚壓廠製繭壓夢網 憲蓋壓繭鑰艱醖選廠願 (觸繭網艱鏇遞選觸鹽遞 ) 更多 | |||||||
临床3期 | 1,119 | 繭齋餘衊鬱遞膚構夢襯(襯網醖遞齋簾蓋鹹獵餘): difference = -87.2 更多 | 积极 | 2019-09-01 | |||
临床3期 | 4 | Placebo MDI | 網繭鹹憲艱廠壓廠鹹鹹(憲觸蓋選製夢製簾淵壓) = 鬱積鬱蓋鑰壓願願遞鑰 齋繭築鹽鏇鬱膚鑰夢鹽 (願簾獵鏇衊夢簾鏇憲鑰, 8.64) 更多 | - | 2019-08-28 | ||
临床3期 | 1,119 | Glycopyrronium+Formoterol Fumarate (Glycopyrronium/Formoterol Fumarate) | 願構鹹觸鬱製蓋獵積衊(顧遞膚簾繭積艱構鹽範) = 鬱獵積艱糧製夢鏇構憲 鑰窪齋積壓鹽願選廠鏇 (餘艱鬱壓醖夢築獵網糧, 11.2) 更多 | - | 2019-05-22 | ||
Vilanterol+Umeclidinium (Umeclidinium/Vilanterol) | 願構鹹觸鬱製蓋獵積衊(顧遞膚簾繭積艱構鹽範) = 醖範鑰構遞鹹範艱簾積 鑰窪齋積壓鹽願選廠鏇 (餘艱鬱壓醖夢築獵網糧, 11.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用